The combination of endocrine therapy with ribociclib, abemaciclib, and ribociclib has become the first-line standard of care (SOC) for locally advanced inoperable or metastatic HR+, HER2− breast cancer patients due to its benefits in progression-free survival and overall survival. This evidence concerns the gene ERBB2 and breast cancer.